With these results, immune checkpoint blockade targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 pathway (PD-1/PD-L1) have been investigated and tested in the treatment of sarcoma. This evidence concerns the gene CD274 and sarcoma.